Good news. A third dose of this vaccine protects against the delta variant

Moderna said its coronavirus booster vaccine produced a “robust” antibody response against a highly contagious delta variant, according to details of a study released Thursday with the company’s second quarter earnings report.

In a phase II trial, Moderna is testing a 50 microgram dose of a three-dose vaccine in people previously vaccinated. The company said the booster injection produced a promising immune response against three different types, including a delta strain of coronavirus, with antibody levels approaching those seen in previously unvaccinated people who received two doses of 100 micrograms.

She added that the data had been submitted to a periodic scientific journal for publication, according to the “CNBC” network, and that “Al-Arabiya.net” had reviewed them.

On the other hand, the company’s trading results exceeded analysts’ average estimates, according to data compiled by Refinitiv, with earnings per share rising to $ 6.46 per share, compared to $ 5.96 per share expected by Refinitiv. analysts.

The company’s quarterly revenue for the second quarter was $ 4.35 billion, compared to an expected $ 4.2 billion.

The new booster dose data comes with a variable delta spread across many countries, including the United States. The CDC has said the delta variant is as contagious as chickenpox and can make older people sicker, even if they are fully vaccinated.

In reports accompanying the work results released Thursday, Moderna said she expects the alternative to lead to an increase in penetrating injuries, which occur in those vaccinated.

Moderna believes that a third booster dose will likely be needed before the winter season.

It comes as the World Health Organization on Wednesday called on rich countries to stop distributing booster vaccines against the Covid virus, highlighting the inequality of vaccines around the world.

Moderna said Thursday that a final analysis of its Phase III study found the two-dose vaccine to be 93% effective, with “survival” effectiveness within six months of receiving the second dose.

In comparison, Pfizer and Biontech said the vaccine’s effectiveness dropped to around 84% six months after the second dose.

Moderna, which was founded in 2010, was the second company to obtain a U.S. license for a corona vaccine after Pfizer-Biontech.The Corona vaccine produced by Moderna generated $ 4.2 billion in sales in the three months ending June 30, according to the results report.

The company said it aims to produce between 800 million and one billion doses of the Corona vaccine this year. It also signed vaccine contracts worth $ 20 billion in sales this year and closed deals worth $ 12 billion in 2022.